• Clinical and Experimental Pediatrics
• /
• 제63권12호
• /
• pp.485-490
• /
• 2020

Background: Recurrent abdominal pain (RAP) is one of the frequent complaints in general practice, particularly in pediatrics and is among the common cause of referral to gastroenterology clinics. Purpose: This study is designed to investigate the effects of probiotics for the treatment of RAP and desired therapeutic outcomes. Methods: One hundred twenty-five children with the diagnosis of RAP according to Rome III criteria for irritable bowel syndrome (IBS), functional abdominal pain (FAP), functional dyspepsia (FD), and abdominal migraine (AM), were enrolled in this double-blind randomized controlled trial. Results: Sixty-five subjects received probiotics, and others received placebo treatment for 4 weeks. Lactobacillus reuteri was therapeutically effective in 32 patients compared to 8 patients, responding to the placebo treatment. Compared to baseline, all pain-related variables showed a significant reduction for the IBS and FD at the end of the 4th week. However, it did not respond well in FAP and AM groups. Pain-related outcomes such as, frequency of the pain, severity, and duration of the pain were decreased following the probiotic treatment. No therapeutic response was seen in AM group after the administration of probiotics. L. reuteri significantly led to pain relief in the overall population, and also in FAP, FD, and IBS subgroups. Conclusion: L. reuteri probiotics are likely to lead to RAP relief and can be recommended for the treatment of functional gastrointestinal disorders.

• Biomolecules & Therapeutics
• /
• 제23권4호
• /
• pp.350-356
• /
• 2015

Functional dyspepsia (FD) is a prevalent idiopathic upper gastrointestinal (GI) disorder characterized by diverse symptomatology including epigastric pain or discomfort, postprandial fullness, and early satiety. Although its pathophysiological mechanisms have not yet been fully established, the available studies suggest that the etiology of FD is invariably multifactorial. Benachio-F$^{(R)}$ (BF) is a proprietary liquid formulation of 7 herbal extracts that has been proposed to address this multifactorial etiology using multi-drug phytotherapy. The pharmacological effects of BF, in comparison with those of two other herbal products (Whalmyungsu$^{(R)}$; WM and Iberogast$^{(R)}$; IB) were evaluated in rats. In a laparotomy-induced rat model of delayed GI transit, BF significantly accelerated the delayed gastric emptying caused by morphine, apomorphine, and cisplatin, and also significantly increased mean gastric transit, as compared to the control animals. BF markedly increased gastric accommodation in rats and produced higher gastric volume values than did the control treatment. The effects of BF were generally comparable or superior to those of WM and IB in these models. Furthermore, BF significantly stimulated biliary flow, as compared to the control treatment. These results indicated that BF might have great potential as an effective phytotherapeutic agent capable of reducing GI symptoms and increasing quality of life in FD patients.

• 대한소화기학회지
• /
• 제72권6호
• /
• pp.286-294
• /
• 2018

Background/Aims: The predictive factors of functional dyspepsia (FD) remain controversial. Therefore, we sought to investigate symptom responses in FD patients after Helicobacter pylori (H. pylori) eradication and used predictive factor analysis to identify significant factors of FD resolution at one-year after commencing eradication therapy. Methods: This prospective, multi-center clinical trial was performed on 65 FD patients that met Rome III criteria and had H. pylori infection. Symptom responses and factors that predicted poor response were determined by analysis one year after commencing H. pylori eradication therapy. Results: A total of 63 patients completed the one-year follow-up. When an eradication success group (n=60) and an eradication failure group (n=3) were compared with respect to FD response rate at one year, results were as follows; complete response 73.3% and 0.0%, satisfactory response 1.7% and 0.0%, partial response 10.0% and 33.3%, and refractory response 15.0% and 66.7%, respectively (p=0.013). Univariate analysis showed persistent H. pylori infection (p=0.021), female gender (p=0.025), and medication for FD during the study period (p=0.013) were associated with poor FD response at one year. However, age, smoking, alcohol consumption, and underlying disease were not found to affect response. Finally, multivariate analysis showed that female gender (OR, 4.70; 95% CI, 1.17-18.88) was the sole independent risk factor of poor FD response at one year after commencing H. pylori eradication therapy. Conclusions: Female gender was found to predict poor response in FD patients despite H. pylori eradication. Furthermore, successful H. pylori eradication appears to be associated with FD improvement, but the number of non-eradicated patients was too small to conclude.

• 대한한방내과학회지
• /
• 제41권6호
• /
• pp.1223-1230
• /
• 2020

Objective: The purpose of this study was to report the effectiveness of Korean medicine (Beewha-eum) on the treatment of non-cardiac chest pain (NCCP) in a patient with non-erosive reflux disease (NERD). Methods: The patient was diagnosed with a spleen-stomach weakness pattern identified by Korean medicine and was treated with herbal medicine (Beewha-eum). The severity of symptoms was assessed with a numerical rating scale (NRS) for chest pain, self-reported dyspepsia degree (%), Korean gastrointestinal symptom rating scale (KGSRS), gastrointestinal symptom score (GIS), and Functional Dyspepsia-Quality of Life(FD-QOL) score. Results: After Beewha-eum treatment, the severity of chest pain was decreased from NRS 8 to NRS 0 and the self-reported dyspepsia degree also decreased from 100% to 65%. The KGSRS score was decreased from 49 to 35, the GIS score was also decreased from 16 to 9, and the FD-QOL score was increased from 20 to 25. Conclusions: The study findings suggested that Korean medical treatment with Beewha-eum could be an effective option for treating NCCP in patients with NERD.

• 정신신체의학
• /
• 제24권1호
• /
• pp.66-73
• /
• 2016

연구목적 소방관에서 기능성 소화불량의 유병률이 높고 기능성 소화불량의 발현과 악화에 심리사회적 요인이 깊이 연관되어 있음에도 불구하고 이에 관한 연구는 매우 부족한 상황이다. 따라서 본 연구에서는 소방관들을 대상으로 기능성 소화불량에 관련되는 심리사회적 요인의 특징을 알아보고 삶의 질에 미치는 영향을 파악하고자 하였다. 방 법 소방관 1,217명을 대상으로 로마 III 진단기준에 따라 기능성 소화불량 집단을 선별하였다. 인구학적 요인을 조사하였으며 심리사회적 요인을 평가하기 위해 Patient Health Questionnaire-9(PHQ-9), Generalized Anxiety Disorder questionnaire-7(GAD-7), Korean Occupational Stress Scale(KOSS), Ways of Coping Checklist(WCCL), Rosenberg's Self-Esteem Scale(RSES) 그리고 World Health Organization Quality of Life Scale abbreviated version(WHOQOL-BREF)를 사용하였다. 기능성 소화불량에 따라 집단을 나누고 교차분석(chisquare test)과 독립표본 t-검정(independent t-test)을 사용하여 집단 간의 차이를 알아보았다. 또한 KOSS의 각 하위 영역별로 기능성 소화불량의 위험도를 평가하기 위해 로지스틱 회귀분석(logistic regres-sion analysis)을 시행하였다. 기능성 소화불량 집단의 삶의 질과 독립변인들의 상관관계를 파악하기 위해 Pearson 상관분석(Pearson's correlation test)을 시행하였으며, 위계적 회귀분석(hierarchical regression anal-ysis)을 통해 기능성 소화불량 집단의 삶의 질에 영향을 미치는 예측 요인을 알아보았다. 결 과 기능성 소화불량 집단은 남성(p=0.006)이 많았고, PHQ-9(p<0.001), GAD-7(p<0.001), KOSS(p<0.001) 점수가 유의미하게 높았으며, RSES(p=0.008), WHOQOL-BREF(p<0.001) 점수는 유의미하게 낮았다. KOSS 하위 영역 중 높은 직무요구도(OR 1.94, 95% CI : 1.29-2.93), 부적절한 보상(OR 2.47, 95% CI : 1.61-3.81), 그리고 불편한 직장 문화(OR 1.51, 95% CI : 1.01-2.24)에서 기능성 소화불량의 위험도가 높았다. 기능성 소화불량 집단의 삶의 질에 대한 최종 회귀모델에서 우울증상과 직무스트레스가 낮고, 자아존중감이 높은 것이 삶의 질의 42.0%를 설명했다. 결 론 본 연구 결과 기능성 소화불량 및 삶의 질에 대한 심리사회적 요인의 영향이 확인되었다. 따라서 향후 기능성 소화불량의 평가에 있어 내과적 접근 뿐만 아니라 정신건강의학과적인 접근이 동시에 이루어져야 할 것으로 판단된다.

• 대한한방내과학회지
• /
• 제39권4호
• /
• pp.732-740
• /
• 2018

Objective: The aim of this study was to find a correlation between the Nepean Dyspepsia Index (NDI) and electrogastrography (EGG) in clinical practice students. Methods: In total, 28 students were enrolled. NDI and EGG were measured in all students. NDI was classified as abnormal when the score was 11 or more. In EGG, standard 1 was classified as abnormal if the preprandial or postprandial percentage of normal gastric slow waves of Ch3 was less than 70% or if power ratio of Ch3 was less than 1. Standard 2 was classified as abnormal if standard 1 was met or if the percentage of normal gastric slow waves of Ch3 decreased after meals. Results: NDI and EGG had no statistically meaningful correlation when standard 1 was used, but NDI and EGG had statistically meaningful correlation when standard 2 was used. Conclusions: These findings suggest that NDI and EGG are correlated and that EGG can be used to evaluate the degree of dyspepsia.

• 대한한방내과학회지
• /
• 제45권3호
• /
• pp.519-531
• /
• 2024

Objectives: This case study reports the effectiveness of Korean medical treatment in a patient with cyclic vomiting syndrome. Methods: A 29-year-old female Korean patient with cyclic vomiting syndrome received acupuncture, electroacupuncture, herbal medicine, and moxibustion for 2 weeks in hospital. Changes in symptoms were evaluated using the Gastrointestinal Symptom Rating Scale (GSRS), Visual Analog Scale (VAS), Index for Nausea, Vomiting, and Retching (INVR), Nausea Severity Scale (NSS), Nepean Dyspepsia Index-Korean version (NDI-K), quality of life using the Functional Dyspepsia Related Quality of Life questionnaire (FD-QoL), and gastric motility using electrogastrography (EGG). Results: Post-treatment, the patient showed high satisfaction and improvement in symptoms of nausea and vomiting. The following changes were observed in scores: GSRS: 23 to 19; VAS of nausea: 88 to 95; VAS of dyspepsia: 95 to 12; INVR: 13 to 1; NSS: 17 to 5; NDI-K: 107 to 78; and FD-QoL 84 to 27. We also found positive results in Channel 3 of EGG parameters, implying the improvement of gastric motility disorder. Conclusion: Korean medical treatment can be a therapeutic option for cyclic vomiting syndrome.

• Journal of Neurogastroenterology and Motility
• /
• 제24권4호
• /
• pp.669-675
• /
• 2018

Background/Aims Functional dyspepsia (FD) and irritable bowel syndrome (IBS) are common gastrointestinal (GI) disorders and these patients frequently overlap. Trimebutine has been known to be effective in controlling FD co-existing diarrhea-dominant IBS, however its effect on overlap syndrome (OS) patients has not been reported. Therefore, we investigated the effect of trimebutine on the model of OS in guinea pigs. Methods Male guinea pigs were used to evaluate the effects of trimebutine in corticotropin-releasing factor (CRF) induced OS model. Different doses (3, 10, and 30 mg/kg) of trimebutine were administered orally and incubated for 1 hour. The next treatment of $10{\mu}g/kg$ of CRF was intraperitoneally injected and stabilized for 30 minutes. Subsequently, intragastric 3 mL charcoal mix was administered, incubated for 10 minutes and the upper GI transit analyzed. Colonic transits were assessed after the same order and concentrations of trimebutine and CRF treatment by fecal pellet output assay. Results Different concentrations (1, 3, and $10{\mu}g/kg$) of rat/human CRF peptides was tested to establish the OS model in guinea pigs. CRF $10{\mu}g/kg$ was the most effective dose in the experimental OS model of guinea pigs. Trimebutine (3, 10, and 30 mg/kg) treatment significantly reversed the upper and lower GI transit of CRF induced OS model. Trimebutine significantly increased upper GI transit while it reduced fecal pellet output in the CRF induced OS model. Conclusions Trimebutine has been demonstrated to be effective on both upper and lower GI motor function in peripheral CRF induced OS model. Therefore, trimebutine might be an effective drug for the treatment of OS between FD and IBS patients.

• 정신신체의학
• /
• 제29권1호
• /
• pp.58-66
• /
• 2021

연구목적 본 연구에서는 기능성위장질환 환자를 과민성 대장 증후군, 기능성 소화불량, 기능성 변비, 기능성 흉부 작열감, 중복집단(두 개 이상의 기능성 질환이 중복)으로 분류하여 정신사회적 특성을 비교하고, 기능성위장질환 환자의 삶의 질과 연관된 요인들을 알아보고자 하였다. 방 법 일 대학병원 소화기 내과 전문의에 의해 기능성 위장질환으로 진단받은 환자 144명을 기능성위장질환 환자 집단으로 선정하였다. 인구통계학적 요인을 조사하였으며 정신사회적 요인을 평가하기 위해 Korean-Beck Depression Inventory-II (K-BDI-II), Korean-Beck Anxiety Inventory (K-BAI), Korean version of Childhood Trauma Questionnaire (K-CTQ), Multi-dimensional Scale of Perceived Social Support (MSPSS), Korean Version of Connor-Davidson Resilience Scale (K-CD-RISC), World Health Organization Quality of Life Assessment Instrument Brief Form (WHOQOL-BREF)를 사용하였다. 결 과 중복집단이 다른 집단에 비해 BDI-II 점수(F=11.09, p<0.001)와 BAI 점수(F=8.93, p<0.001)가 유의하게 높았다. 아동기 외상에서 정서적 방임(F=2.54, p=0.04)은 IBS 환자집단이 FD 환자 집단에 비해 유의하였다. FGID 환자에서 삶의 질은 우울증상(r=-0.196, p<0.01), 불안(r=-0.235, p<0.01), 아동기 트라우마(r=-0.222, p<0.01)와 음의 상관관계를 보였고, 사회적 지지(r=0.512, p<0.01), 회복탄력성(r=0.581, p<0.01)과는 양의 상관관계를 나타냈다. 결 론 연구결과 중복 환자 집단에서 우울, 불안이 유의하게 높았으며 아동기 외상에서 IBS 환자 집단이 FD 환자 집단보다 정서적 방임이 유의하게 높았다. 따라서 추후 기능성 위장질환 환자의 치료에 있어 정신사회적 요인에 대한 적극적인 개입이 요구된다고 하겠다.

• Journal of Microbiology and Biotechnology
• /
• 제32권4호
• /
• pp.405-418
• /
• 2022

Simotang oral liquid (SMT) is a traditional Chinese medicine (TCM) consisting of four natural plants and is used to alleviate gastrointestinal side effects after chemotherapy and functional dyspepsia (FD). However, the mechanism by which SMT helps cure these gastrointestinal diseases is still unknown. Here, we discovered that SMT could alleviate gastrointestinal side effects after chemotherapy by altering gut microbiota. C57BL/6J mice were treated with cisplatin (DDP) and SMT, and biological samples were collected. Pathological changes in the small intestine were observed, and the intestinal injury score was assessed. The expression levels of the inflammatory factors IL-1β and IL-6 and the adhesive factors Occludin and ZO-1 in mouse blood or small intestine tissue were also detected. Moreover, the gut microbiota was analyzed by high-throughput sequencing of 16S rRNA amplicons. SMT was found to effectively reduce gastrointestinal mucositis after DDP injection, which lowered inflammation and tightened the intestinal epithelial cells. Gut microbiota analysis showed that the abundance of the anti-inflammatory microbiota was downregulated and that the inflammatory microbiota was upregulated in DDP-treated mice. SMT upregulated anti-inflammatory and anticancer microbiota abundance, while the inflammatory microbiota was downregulated. An antibiotic cocktail (ABX) was also used to delete mice gut microbiota to test the importance of gut microbiota, and we found that SMT could not alleviate gastrointestinal mucositis after DDP injection, showing that gut microbiota might be an important mediator of SMT treatment. Our study provides evidence that SMT might moderate gastrointestinal mucositis after chemotherapy by altering gut microbiota.